-
Je něco špatně v tomto záznamu ?
Reduction of Doxorubicin-Induced Cardiotoxicity Using Nanocarriers: A Review
M. Fojtu, J. Gumulec, T. Stracina, M. Raudenska, A. Skotakova, M. Vaculovicova, V. Adam, P. Babula, M. Novakova, M. Masarik,
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, přehledy
- MeSH
- antibiotika antitumorózní aplikace a dávkování škodlivé účinky MeSH
- doxorubicin aplikace a dávkování škodlivé účinky MeSH
- kardiotoxicita diagnóza prevence a kontrola MeSH
- lidé MeSH
- nádory farmakoterapie MeSH
- nanočástice aplikace a dávkování MeSH
- nosiče léků aplikace a dávkování MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
BACKGROUND: Anthracycline antibiotic doxorubicin (DOX) is a very potent and extensively prescribed chemotherapeutic drug. It is widely utilized in the therapy of variety of haematological and solid tumours, although its administration is commonly accompanied with several severe side effects. The most serious one is a development of dose-dependent and cumulative cardiotoxicity. In the course of time, many strategies have been investigated in order to avoid or at least to diminish DOX-induced cardiac dysfunction; these include reduction of toxic effect by coadministration with iron chelators (dexrazoxane), trastuzumab, taxanes, statins, and ACE-inhibitors. However, the attenuation of cardiotoxic effect is still not satisfactory yet. OBJECTIVE: This review represents an overall appraisal of studies concerning with the utilization of various doxorubicinloaded nanoparticles in the cancer treatment with specific emphasis on those studies evaluating their influence on the reduction of heart tissue damage. CONCLUSION: Introduction of nanoscale drug delivery systems undoubtedly represents nowadays one of the most promising tools for lowering systemic toxicity. Nanoparticles enable to target the therapeutic payload directly towards the tumor tissue, thus leading to the increased accumulation of the drug in the desired tissue and simultaneously protecting surrounding healthy tissues.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18025203
- 003
- CZ-PrNML
- 005
- 20180712093725.0
- 007
- ta
- 008
- 180709s2017 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.2174/1389200218666170105165444 $2 doi
- 035 __
- $a (PubMed)28059036
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Fojtu, Michaela $u Department of Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, CZ-625 00 Brno. Czech Republic.
- 245 10
- $a Reduction of Doxorubicin-Induced Cardiotoxicity Using Nanocarriers: A Review / $c M. Fojtu, J. Gumulec, T. Stracina, M. Raudenska, A. Skotakova, M. Vaculovicova, V. Adam, P. Babula, M. Novakova, M. Masarik,
- 520 9_
- $a BACKGROUND: Anthracycline antibiotic doxorubicin (DOX) is a very potent and extensively prescribed chemotherapeutic drug. It is widely utilized in the therapy of variety of haematological and solid tumours, although its administration is commonly accompanied with several severe side effects. The most serious one is a development of dose-dependent and cumulative cardiotoxicity. In the course of time, many strategies have been investigated in order to avoid or at least to diminish DOX-induced cardiac dysfunction; these include reduction of toxic effect by coadministration with iron chelators (dexrazoxane), trastuzumab, taxanes, statins, and ACE-inhibitors. However, the attenuation of cardiotoxic effect is still not satisfactory yet. OBJECTIVE: This review represents an overall appraisal of studies concerning with the utilization of various doxorubicinloaded nanoparticles in the cancer treatment with specific emphasis on those studies evaluating their influence on the reduction of heart tissue damage. CONCLUSION: Introduction of nanoscale drug delivery systems undoubtedly represents nowadays one of the most promising tools for lowering systemic toxicity. Nanoparticles enable to target the therapeutic payload directly towards the tumor tissue, thus leading to the increased accumulation of the drug in the desired tissue and simultaneously protecting surrounding healthy tissues.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antibiotika antitumorózní $x aplikace a dávkování $x škodlivé účinky $7 D000903
- 650 _2
- $a kardiotoxicita $x diagnóza $x prevence a kontrola $7 D066126
- 650 _2
- $a doxorubicin $x aplikace a dávkování $x škodlivé účinky $7 D004317
- 650 _2
- $a nosiče léků $x aplikace a dávkování $7 D004337
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nanočástice $x aplikace a dávkování $7 D053758
- 650 _2
- $a nádory $x farmakoterapie $7 D009369
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Gumulec, Jaromir $u Department of Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, CZ-625 00 Brno. Czech Republic.
- 700 1_
- $a Stracina, Tibor $u Department of Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, CZ-625 00 Brno. Czech Republic.
- 700 1_
- $a Raudenska, Martina $u Central European Institute of Technology, Brno University of Technology, Purkynova 123, CZ-612 00 Brno. Czech Republic.
- 700 1_
- $a Skotakova, Anna $u Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, CZ-625 00 Brno. Czech Republic.
- 700 1_
- $a Vaculovicova, Marketa $u Central European Institute of Technology, Brno University of Technology, Purkynova 123, CZ-612 00 Brno. Czech Republic.
- 700 1_
- $a Adam, Vojtech $u Department of Chemistry and Biochemistry, Mendel University in Brno, Zemedelska 1, CZ-613 00 Brno. Czech Republic.
- 700 1_
- $a Babula, Petr $u Department of Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, CZ-625 00 Brno. Czech Republic.
- 700 1_
- $a Novakova, Marie $u Department of Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, CZ-625 00 Brno. Czech Republic.
- 700 1_
- $a Masarik, Michal $u Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, CZ-625 00 Brno. Czech Republic.
- 773 0_
- $w MED00007901 $t Current drug metabolism $x 1875-5453 $g Roč. 18, č. 3 (2017), s. 237-263
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28059036 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180709 $b ABA008
- 991 __
- $a 20180712094018 $b ABA008
- 999 __
- $a ok $b bmc $g 1317334 $s 1022124
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 18 $c 3 $d 237-263 $i 1875-5453 $m Current drug metabolism $n Curr Drug Metab $x MED00007901
- LZP __
- $a Pubmed-20180709
